Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MF1 first-in-human safety and pharmacokinetics study in healthy adults and Parkinson's disease patients
jRCT2021260006Phase 1Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MF1 in Parkinson's disease (PD) (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Pharmacokinetics and Safety. Started Jun 2026; status: recruiting.
02
Drugs
MF1
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2021260006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021260006.